# EsoCa Systemic Therapy {#eso_systemic}

## Immunotherapy

RAMONA trial: Ipi/Nivo second-line therapy for esophageal squamous cell carcinoma. [@eberte417]. 66 patients treated with ipi/nivo or nivo. Median survival 7.2 months, longer than historical controls. One treatment-related death.
